Merck, Inc.
🇵🇭Philippines
A Study to Observe Characteristics of Rheumatoid Arthritis in Patients Using Infliximab (Study P04250)
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 728
- Registration Number
- NCT00705289
Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)
Completed
- Conditions
- Hepatitis C, ChronicHepacivirus
- Interventions
- Biological: Peginterferon alfa-2b (SCH 54031)Drug: Ribavirin (SCH 18908)
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 789
- Registration Number
- NCT00705666
Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)
Completed
- Conditions
- Crohn's Disease
- Interventions
- Biological: Remicade
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2662
- Registration Number
- NCT00705614
European Safety Registry in Ulcerative Colitis (P04808)
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: infliximabDrug: Standard Therapy
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2239
- Registration Number
- NCT00705484
Impact of Infliximab in Fistulizing Crohn's Disease on Health Care Resources (Study P04204)(TERMINATED)
Terminated
- Conditions
- Crohn Disease
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2015-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT00705471
Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2015-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 180
- Registration Number
- NCT00705419
Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)
Completed
- Conditions
- Hepatitis C, ChronicHepacivirus
- Interventions
- Biological: Peginterferon alfa-2b (SCH 54031)Drug: Ribavirin (SCH 18908)Behavioral: Patient assistance program
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 601
- Registration Number
- NCT00704522
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
Completed
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 180
- Registration Number
- NCT00704808
Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)
Completed
- Conditions
- Hepatitis C, ChronicHepatitis C
- Interventions
- Biological: PegIntron (peginterferon alfa-2b; SCH 54031) penDrug: Rebetol (ribavirin; SCH 18908)
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 185
- Registration Number
- NCT00704717
Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 746
- Registration Number
- NCT00704964
© Copyright 2025. All Rights Reserved by MedPath